Ongoing Project

- Development of Paclitaxel Micellar, a Cremophor-free formulation of paclitaxel,
is underway for the ovarian cancer treatment.
- Increased convenience without prior treatment by applying patent-applied Micelle coating.
- An optimal mixture of Paclitaxel based on the form of additives developed to reduce side effects.

* It received a marketing authorization by the European Medicines Agency (EMA)
under the name of medical product Apealea® (paclitaxel micellar) in 2018,
and is currently being commercialized in Europe and in the Middle East and North Africa (MENA) region.

XR17 Technology Platform

Ovarian cancer

Cancer of the ovaries or fallopian tubes is a serious disease that often leads to death if it is detected late and metastases have formed. The early symptoms are non-specific and vague, leading to a disease that is difficult to diagnose. The overall occurrence of new cases globally is between 5 – 15 cases per 100,000 individuals.2 In Western Europe and the US, the incidence is between 6 – 8 cases per 100,000.3 Almost 300,000 women are estimated to develop the disease each year worldwide, of which approximately 700 cases in Sweden.4

* source: https://www.oasmia.com/en/market-human-health/